Literature DB >> 34416168

Tumor organoids: Opportunities and challenges to guide precision medicine.

Vivien Veninga1, Emile E Voest2.   

Abstract

Tumor organoids have been proposed as a model system for precision medicine. The ability of tumor organoids to retain characteristics of the original tumor makes them unique for cancer research on an individual patient level. Hence, the idea to use tumor organoids for clinical decision making and optimize patient outcome is tempting. In vitro responses of tumor organoids to a wide array of drugs have been positively correlated to patient responses. However, substantial challenges remain and prospective studies with large cohorts are highly needed before implementation in clinical cancer care can be considered. Because of their personalized characteristics and the immediate link with patient data, tumor organoids also have great potential in preclinical research. Here, we provide a critical overview of both clinical and preclinical advances using tumor organoids.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cancer; clinical implementation; precision medicine; preclinical research; tumor organoids

Mesh:

Substances:

Year:  2021        PMID: 34416168     DOI: 10.1016/j.ccell.2021.07.020

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  19 in total

1.  Enhanced phosphorylation of c-Jun by cisplatin treatment as a potential predictive biomarker for cisplatin response in combination with patient-derived tumor organoids.

Authors:  Yoshiyuki Tsukamoto; Shusaku Kurogi; Tomotaka Shibata; Kosuke Suzuki; Yuka Hirashita; Shoichi Fumoto; Shinji Yano; Kazuyoshi Yanagihara; Chisato Nakada; Fumi Mieno; Keisuke Kinoshita; Takafumi Fuchino; Kazuhiro Mizukami; Yoshitake Ueda; Tsuyoshi Etoh; Tomohisa Uchida; Toshikatsu Hanada; Mutsuhiro Takekawa; Tsutomu Daa; Kuniaki Shirao; Shuichi Hironaka; Kazunari Murakami; Masafumi Inomata; Naoki Hijiya; Masatsugu Moriyama
Journal:  Lab Invest       Date:  2022-08-03       Impact factor: 5.502

Review 2.  Towards precision oncology with patient-derived xenografts.

Authors:  Eugenia R Zanella; Elena Grassi; Livio Trusolino
Journal:  Nat Rev Clin Oncol       Date:  2022-09-23       Impact factor: 65.011

3.  3-Dimensional Model to Study Apoptosis Induction of Activated Natural Killer Cells Conditioned Medium Using Patient-Derived Colorectal Cancer Organoids.

Authors:  Benyamin Parseh; Ayyoob Khosravi; Abdolreza Fazel; Jafar Ai; Somayeh Ebrahimi-Barough; Javad Verdi; Majid Shahbazi
Journal:  Front Cell Dev Biol       Date:  2022-05-26

Review 4.  Multimodal predictors for precision immunotherapy.

Authors:  L M Roelofsen; P Kaptein; D S Thommen
Journal:  Immunooncol Technol       Date:  2022-03-01

5.  The drug-induced phenotypic landscape of colorectal cancer organoids.

Authors:  Johannes Betge; Niklas Rindtorff; Jan Sauer; Benedikt Rauscher; Clara Dingert; Haristi Gaitantzi; Frank Herweck; Kauthar Srour-Mhanna; Thilo Miersch; Erica Valentini; Kim E Boonekamp; Veronika Hauber; Tobias Gutting; Larissa Frank; Sebastian Belle; Timo Gaiser; Inga Buchholz; Ralf Jesenofsky; Nicolai Härtel; Tianzuo Zhan; Bernd Fischer; Katja Breitkopf-Heinlein; Elke Burgermeister; Matthias P Ebert; Michael Boutros
Journal:  Nat Commun       Date:  2022-06-06       Impact factor: 17.694

Review 6.  Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations.

Authors:  Anthony Letai; Patrick Bhola; Alana L Welm
Journal:  Cancer Cell       Date:  2021-12-23       Impact factor: 31.743

7.  Normal and tumor-derived organoids as a drug screening platform for tumor-specific drug vulnerabilities.

Authors:  Camilla Calandrini; Jarno Drost
Journal:  STAR Protoc       Date:  2022-01-10

8.  Patient-derived organoids for personalized gallbladder cancer modelling and drug screening.

Authors:  Bo Yuan; Xiaofang Zhao; Xiang Wang; Erdong Liu; Chunliang Liu; Yali Zong; Youhai Jiang; Minghui Hou; Yao Chen; Lei Chen; Yongjie Zhang; Hongyang Wang; Jing Fu
Journal:  Clin Transl Med       Date:  2022-01

9.  Editorial: Recent 3D Tumor Models for Testing Immune-Mediated Therapies.

Authors:  Jacques Zimmer; Roberta Castriconi; Silvia Scaglione
Journal:  Front Immunol       Date:  2021-11-18       Impact factor: 7.561

10.  Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids.

Authors:  Qingda Meng; Shanshan Xie; G Kenneth Gray; Mohammad H Dezfulian; Weilin Li; Ling Huang; Dipikaa Akshinthala; Elizabeth Ferrer; Catherine Conahan; Sofia Perea Del Pino; Joseph Grossman; Stephen J Elledge; Manuel Hidalgo; Senthil K Muthuswamy
Journal:  J Immunother Cancer       Date:  2021-11       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.